{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Free Realtime Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchangeTimezoneName": "Europe/Stockholm", "exchangeTimezoneShortName": "CEST", "currency": "SEK", "market": "se_market", "esgPopulated": false, "gmtOffSetMilliseconds": 7200000, "exchange": "STO", "longName": "Egetis Therapeutics AB (publ)", "shortName": "Egetis Therapeutics AB", "regularMarketPrice": 7.8, "regularMarketChangePercent": 0.6451638, "messageBoardId": "finmb_33840529", "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.15217388, "fiftyTwoWeekLow": 3.005, "fiftyTwoWeekHigh": 9.2, "earningsTimestamp": 1682506740, "earningsTimestampStart": 1682506740, "earningsTimestampEnd": 1682506740, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 4.795, "fiftyTwoWeekLowChangePercent": 1.5956738, "fiftyTwoWeekRange": "3.005 - 9.2", "fiftyTwoWeekHighChange": -1.3999996, "epsTrailingTwelveMonths": -1.09, "epsForward": 1.18, "epsCurrentYear": -1.08, "priceEpsCurrentYear": -7.2222223, "sharesOutstanding": 249588992, "bookValue": 2.519, "fiftyDayAverage": 6.8402, "fiftyDayAverageChange": 0.95980024, "fiftyDayAverageChangePercent": 0.14031757, "twoHundredDayAverage": 5.32385, "twoHundredDayAverageChange": 2.47615, "twoHundredDayAverageChangePercent": 0.46510515, "marketCap": 1979452800, "forwardPE": 6.61017, "priceToBook": 3.0964668, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "PledPharma AB", "nameChangeDate": "2023-05-14", "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1302159600000, "priceHint": 2, "regularMarketChange": 0.05000019, "regularMarketTime": 1684143414, "regularMarketDayHigh": 7.94, "regularMarketDayRange": "7.68 - 7.94", "regularMarketDayLow": 7.68, "regularMarketVolume": 62540, "regularMarketPreviousClose": 7.75, "bid": 7.8, "ask": 7.85, "fullExchangeName": "Stockholm", "financialCurrency": "SEK", "regularMarketOpen": 7.86, "averageDailyVolume3Month": 681296, "averageDailyVolume10Day": 416157, "symbol": "EGTX.ST"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Klara Norra Kyrkogata 26", "city": "Stockholm", "zip": "111 22", "country": "Sweden", "phone": "46 86 79 72 10", "fax": "46 86 63 57 25", "website": "https://www.egetis.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.", "fullTimeEmployees": 20, "companyOfficers": [{"maxAge": 1, "name": "Mr. Nicklas  Westerholm", "age": 46, "title": "Chief Exec. Officer", "yearBorn": 1976, "fiscalYear": 2021, "totalPay": {"raw": 4225000, "fmt": "4.22M", "longFmt": "4,225,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Torsten  Alm\u00e9n", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ingemar  Lundstr\u00f6m", "age": 79, "title": "Founder", "yearBorn": 1943, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Louis Joseph Ignarro Ph.D.", "age": 80, "title": "Founder", "yearBorn": 1942, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Associate Prof. Heidi  Brurok", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rob  Towart", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Yilmaz  Mahshid Ph.D.", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Katayoun  Welin-Berger Ph.D.", "age": 54, "title": "VP of Operations & Technical Operations", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jacques  N\u00e4sstr\u00f6m M.B.A., MBA, Ph.D.", "age": 63, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2017, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Karl  Hard Ph.D.", "age": 60, "title": "VP, Head of Investor Relations & Communication", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}